Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17414393 | 1.00 | TSHR (0.56) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| SCHEMBL28318493 | 0.98 | TSHR (0.54) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| Water SCHEMBL7156214 | 0.98 | TSHR (0.54) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| SCHEMBL28416 | 0.93 | TSHR (0.54) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| SCHEMBL18388973 | 0.93 | TSHR (0.54) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| SCHEMBL18215382 | 0.93 | TSHR (0.54) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| Trimethylammonium SCHEMBL14720864 | 0.92 | TSHR (0.48) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| SCHEMBL1266842 | 0.91 | TSHR (0.52) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| Aluminum Chloride Anhydrous SCHEMBL27976113 | 0.89 | TSHR (0.45) | TSHRSMN1; SMN2GAANLRP3KCNH2 | |
| SCHEMBL1195857 | 0.88 | TSHR (0.64) | TSHRSMN1; SMN2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117802324-B | Method for efficiently extracting active lithium from negative electrode of waste lithium battery | 华中科技大学 | 2025-01-14 | — | — | CN | claimed |
| CN-118943306-A | Zinc metastanniate negative electrode material and preparation method and application thereof | 中国地质大学（武汉） | 2024-11-12 | — | — | CN | claimed |
| WO-2024088400-A1 | PHOSPHORUS-CONTAINING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2024-05-02 | — | — | WO | claimed |
| WO-2024088399-A1 | PHOSPHORUS-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2024-05-02 | — | — | WO | claimed |
| US-20240122941-A1 | THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER | NATIONAL CANCER CENTER (JP) | 2024-04-18 | — | — | US | claimed |
| CN-117802324-A | Method for efficiently extracting active lithium from negative electrode of waste lithium battery | 华中科技大学 | 2024-04-02 | — | — | CN | claimed |
| CN-117790961-A | Method for directly recycling and regenerating waste energy storage lithium battery by using regeneration liquid | 华中科技大学 | 2024-03-29 | — | — | CN | claimed |
| CN-117393705-A | Chemical prelithiation method for preparing organic anode material with high first coulombic efficiency | 重庆理工大学 | 2024-01-12 | — | — | CN | claimed |
| CN-115000489-A | Interface regulation liquid for prelithiation electrode, preparation method and application | 中国科学院物理研究所 | 2022-09-02 | — | — | CN | claimed |
| CN-112490394-B | Chemical prelithiation method for graphite electrode of lithium ion battery | 武汉大学 | 2022-03-25 | — | — | CN | claimed |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012097274-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATION (US) | 2012-07-19 | — | — | WO | claimed |
| US-7825146-B2 | Sulfonamide derivative having isoxazole ring | SHIONOGI & CO., LTD. (JP) | 2010-11-02 | — | — | US | claimed |
| EP-1435957-B1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMA (US) | 2009-06-17 | — | — | EP | claimed |
| CN-101089231-A | Electrolytic oxidation coupling of aryl-1,3-dicarbonyl compound and oxolane type high efficient PAF antagonist (anti)-2-5 II (3,4,5 trimethoxyphenyl) oxolane and synthesis method of its analogue | YUNAN UNIV (CN) | 2007-12-19 | — | — | CN | claimed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | claimed |
| US-6503926-B2 | Nitrogen heterocycle compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-07 | — | — | US | claimed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | claimed |
| US-6288083-B1 | ADMINISTERING COMOUNDS SUCH AS 4-(4-CHLOROPHENYL)-1-(4-(3-METHOXYPHENYL)-4-(3-PYRIDINYL)-3 -BUTENYL)PIPERIDIN-4-OL TO TREAT DISEASES ASSOCIATED WITH ABERRANT LEUKOCYTE RECRUITMENT AND/OR ACTIVATION | MILLENNIUM PHARMACEUTICALS, INC. | 2001-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | TSHR 4868/4885SMN1; SMN2 1876/4885GAA 38/4885 |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | TOP1, TOP2A, TOP2B | TSHR 3707/4885SMN1; SMN2 4216/4885GAA 619/4885 |
| US-20240122941-A1 | THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER | SMARCC1, SMARCA4, SMARCC2 | TSHR 3169/4885SMN1; SMN2 914/4885GAA 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.